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Phtsmin mai,dy cle;tved the ArlI~,$eP bond o1' ArlpVaI.Leu.Pro.Arll.inletleukin.8 (AVLPR-IL-a} produced by human derm.I Itbroblast=t, which 
r¢=ulted in the conversion orAVLPR.IL.8 to IL.~t and the in,clive pentapeptide, though, minor cleavall~ of AVLPR-IL.It by phtsmin at Ly~':,Ght'* 
bond occurred. 
Interl~ukin I~; Fibroblasl; Pla~min: Neutrophil chemolaCti¢ Factor 
I .  iNTRODUCCTION 
In recent years it has become clear that a novel 
neutrophil chemotactic factor, IL-8, is secreted b~ 
several types of cells including monocytes, fibroblasts 
and endothelial cells in response to IL.1 and tumor 
necrosis factor [1-61. The IL.8 is a peptide consisting 
of 72 amino acid residues, and its amino acid sequence 
is identical to the deduced amino acid sequence of a 
fragment of  the 3.10(2 eDNA sequence [7]. Recently it 
has been demonstrated that human fibroblasts 
stimulated with cytokines mainly produce AVLPR- 
IL-8 (FDN(2F) which is the NH.,-terminal extended 
77-residue variant of IL-8 [8-10], We report here that 
plasmin, an important proteinase in the regulation of 
inflammation, mainly cleaves FDN(2F to IL-8 and the 
reactive AVLPR pentapeptide. 
2. MATERIALS AND METHODS 
2.1. Purtfication of FDNCF 
Human dermal fibroblasts (SF-TY cell line) were maintained in
Dulbecco's modified Eagle's medium supplemented with 5°7o fetal 
calf sert~,m, 25 mM Hepes, penicillin (0, I mg/ml) and streptomycin 
(O. 1 mg/ml) until they reached confluence. The cells were cultured in 
serum-free culture medium supplemented with tO "m M recombinant 
human IL-I# and 0.1o70 bovine serum albumin. After culture for 2 
days, cell.free conditioned medium was obtained by centrifugation at
1600× g for 20 rain. The chemoattractant i  he conditioned medium 
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FDNCF fibroblast-derived neutrophil chemot~ctic factor; RP. 
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was purified essentially ns described previously [11]; the sample was 
chromatoliraphedsequential/y on CM-Seph~dex, Sephadex O-?$ and 
RP-HPLC, 
2.2. Tree/men/of FDNCF =+'ith plasmin 
FDNCF (40 j+g) in a final volume of 0,2 ml ¢0f 50 mM Tris.HCI 
buffer (pH 8.0) was incubated with 0,gpg of plasmin (purified from 
human plasma; Sigma, MO. USA) at 37*C for 30 rain, and the rent. 
lion was stopped by the addition of leupeptin (final 1 raM), The reae. 
lion mixture was concentrated by a Speed-Vac entrifuge, dissolved 
in 6 M 8uanidine solution and loaded onto a C.18 reverse-phase col. 
umn (0.45 x l$cm; ODS.120T, Tosoh Co, Tokyo, Japan). 
Chemotaetic factors were ehtted with a linear co~centration gradient 
of aeetonitrile from 0% to 50.4% in 0.05% trifluoroacetic acid at z~ 
flow rate of 0.8 ml/min, 
Neutrophil chemotaxls of plasmin.treated FDNCF was performed 
in vitro by using rat and human neutrophils as described previously 
[121, As an index of ehemotaxis, the number of neutrophils migrated 
into the lower chamber was expressed as percentage (migration rate) 
of that of neutrophils applied in the upper chamber, $DS-PAGE was 
carried out on a slab gel of a discontinuous 9,6%/16,507o acrylamide 
in tricine buffer system [13]. 
2.3. NH2.terminal tnino acid sequencing analysis 
NH,-terminal amino acid sequence determination was performed 
by automated Edman degradation on a gas-plmse protein sequencer 
(model 470A, Applied Biosystems, CA, USA) e¢~uipped with a PTH 
analyzer (model 120A HPLC system). 
3. RESULTS AND DISCUSSION 
Human dermal fibroblasts timulated with 10 -t° M 
IL-1 mainly produced FDNCF, which is the 
NH2-termina] extended 77-residue variant of IL-8 
(AVLPR-IL-8). The homogeneity of the purified 
FDNCF was confirmed by SDS-PAGE, its 
NH2-terminal amino acid sequence and its COOH- 
terminal amino acid determination. We found that the 
purified FDNCF attracts human neutrophils, but rat 
neutrophils are not attracted by the FDNCF at concen- 
trations less than 10 -8 M. On the other hand, I0 -s M 
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IL.8 attracts both rat and human neutrophils. The 
results indicate that rat neutrcphils are attracted by 
II.-8, but not by FDNCF at a concentration of 10 "~ M. 
In the present studies, therefore, we used rat 
neutrophils at about 10," M concentration of attrac- 
tants in chemotaxis assay to determine the conversion 
o f  FDNCF to IL-8 by plasmin. 
Wher FDNCF was incubated with various amounts 
o f  ptasmin, the reaction mixture dose-dependently in-
creased the chemotactic activity for rat neutrophils 
(Fig, IA). The chemotactic activity of  the reaction mtx- 
ture rapidly increased and reached a maximum within 
40 rain when FDNCF (l .4,ag) was incubated with 
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Fig. 2. RP-HPLC of the purified FDNCF (A) and the plasmin- 
treated FDNCF (B). Chemotactic activity of each fraction was 
assayed at 3 × 10 -8 M in duplicate. Experimental conditions are 
described in section 2. 
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Fi~, 3, Nt.l=.tecmlnal mino acid ~equence~ of peak~ l, ~ a=tcl 3 
i~.olated front the plasmin.¢reated FDNCF by RP-HPLC (Fig. 29), 
Th~ amino add rcddu¢~ identified by protein ~¢quencer ar~ marked 
by arrc~w~ under Ih¢ residtl¢~. Partial sequence; of IL.8 and the 
FDNCF purified from conditioned medium of SF,'rY cdl cul=ure are 
shown. 
plasmin (30 ng) at 37=C (Fig. IB) .  The results suggest 
that IL-8 is rapidly formed from FDNCF by plasmin. 
The reaction products of plasmin-treated FDNCF 
were isolated by RP-HPLC to conf irm the formation 
o f  IL-8. The RP-HPLC revealed one major  peak (peak 
2) and two minor peaks (peaks 1 and 3); the area of 
peak 2 was about 90¢1o of total peak areas on RP- 
HPLC (Fig. 2 r . .Peaks  2 and 3 had chemotactic activi- 
ty for rat neutrophils, but chemotactic activity was ot 
found in peak 1 (Fig. 2B). 
The peaks 1-3 obtained from the RP-HPLC were 
concentrated and loaded onto a gas-phase protein se- 
quencer. NH2-terminal amino  acid sequences of peaks 
I -3  are summarized in Fig, 3, The sequence of  peak ] 
is AVLPR,  aud the subsequential mino acid was not 
detected (Fig. 3). In addition, amino acid analysis of 
peak 1 showed that the peptide of  peak 1 is constituted 
by Ala, Val, Leu, Pro  and Arg in equal number of 
moles (data not shown). The results indicate that peak 
1 is the pentapeptide, AVLPR.  
NHz-terminal amino acid sequence of  peak 2 was 
identical to that of  IL-8 (Fig. 3), and other sequences 
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Fig. 4. SDS-PAGE of FDNCF, peak 2 and peak 3. Peaks 2 and 3 
were isolated from the plasmin-treated FDNCF (Fig. 2B). Jne 
disulfide bonds of samples were reduced with 25% (v/v) 
2-mercaptoethanol, and subjected to SDS-PAGE. The molecular 
mass standards (Std) were run simultaneously. 
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includin= FDNCF were not found in siInifl~ant 
amount= by NHrterminal  sequence ~nalysls of" peak 2. 
although FDNCF and IL-8 were eluted at the same 
retention time on RP-HPLC (Fi~, 2A and B). The 
resultssuEtest that FDNCF was almost ¢ompletell/con- 
vetted to [L.8 by pin=rain under the present conditions. 
The carboxypeptidase A treatment of peak 2 and 
FDNCF resulted in the release of the same amino acid, 
Ser which is identical to carboxy-terminal amino acid 
of [L-8 (data not shown). In addition, both the peak 2 
and FDNCF revealed a similar molecular mass (about 
6.4 kDa) on SDS-PAGE (Fig. 4). "*fhe results indicate 
that peak 2 is IL-8 with 72 amino acids, On the basis 
of NH=-terminal mino acid sequence nf peak 3 (Fig, 3) 
and the molecular mass of peak 3 which was similar to 
that of  FDNCF (Fig, 4), it is probable that peak 3 is the 
NH=-terminal truncated 69-amino acid variant of IL-8, 
The ratio of  peak 2 (IL-8)/peak 3 was about 9: l on the 
basis o f  the area of  each peak on RP-HPLC (Fig, 2B), 
suggesting that plasmin mainly cleaves the ArgS-Ser ~ 
bond, and the partial cleavage of Lys~-Giu 9bond may 
occur as a result of the secondary attack of plasmin, 
Plasmin did not cleave any other Arg -X  and Lys -X  
bonds of FDNCF under the present experimental con- 
ditions, This stability of FDNCF except for 
NHz-terminal portion may be due to the fact that IL.8 
contains a triple stranded anti-parallel P-sheet structure 
and a long COOH-terminal hcIL,~ [14,15]. 
It can be assumed that plasmin is generated from 
plasminogen by plasminogen activator which is 
secreted by the stimulated inf lammatory cells including 
monocytes/macrophages and endothelial cells in the in. 
f lammatory region [16], In the present study we have 
shown for the first time that plasmin is responsible for 
the limited proteolysis of FDNCF; plasmin can selec- 
tively cleave FDNCF to IL-8 and the inactive AVLPR 
pentapeptide, though a minor secondary reaction 
occurs. 
A¢lmuwledxememx: We iI~tnk OBuka Phatm~eulk~tl Co. Ltd, 
tTt~kushima, Japan} and Japan¢~ Canwr Research Reso~r~o Bank 
¢Tokyo. Japan| for ~h¢tr i!=nero~ llltt~ or re¢~mblaam human IL. I# 
and ~F-TY gelh. respegtively. We al~o Ihank Dr K. Walan~tbe for 
helpful d|i~ulSlOlB, 
REFERENCES 
[11 Yoshlmura, T., Malsu~hima, K , Tanaka, $., Robinson, E,A,, 
Appalls, E,. Oppenl~elm, J,J, and Leonard, E.J, (|9#'/) Prec, 
N~tl, Aged. Sol. USA 84, 9233-9237. 
[21 Walx, A,, Peveri, P,, Aschauer, H. and Balllioiini, M. (19#?} 
Bier:hem, BIophys, Res. Commun, 149. `/$$-761. 
[3] $~:hrodcr, J.-M,, Mrowlel=, U., Merits. E. and Christopher=, 
E. (1987) J. lmmunol, 139, 34'/4=3483, 
14] Van Dammc, J,, Van Beeumen, J , Opdertakker, G. and Biliau, 
A, (1988) J, Exp. Mad, 167. 1364~1376, 
[~} Larsen. C,G,, Anderson, A.O, App©lla, E , Oppenh¢im, J.J, 
and Malsushinla K. (1989} Setence 243, 1464-1466. 
[6} Baaliolini, M,. Walt, A. and Kunkel, S,L, (1989) J. Cltn: 
Invest 84, 1045-1049, 
['/] $¢hmld, J, and Weissmann. C. (198T} J. [mmunol. 139, 
2~0-256. 
[8] Schroder, J,.M.. Sticherling, M., Henneicke, H.H,, Pteissn©r, 
W.C. and Christopher=, E, (1990) J. lmmunol. 144, 
2223-2232. 
[9] Van D~mm©, J., De¢ock, B., Coning=, R,, Lenacr|s, J,.P,, 
OlvJenakker. G. and Billiau, A. (1989) Eur, J. lmmunol, 19, 
189- 1194. 
[10] Golds, E,E,, Mason. P. and Nyirkos, P. 0989) Biochem, J, 
259. 585-588 
lit} Watanabe, K,, Kinoshita, S, ~nd Nakal~awa, H. (1989) Bio. 
cllem, Biophys, Res. Commun. t6l, 1093-1099. 
[12] Watanab¢, K,, Nakagawa, H, and Tsurufuji, S. (1985) Jap, J, 
Pharmaco]. 39, I02-I04 
[13] Schagser, H. and Von Jagow, G. (1987) Anal, Biochem. 166, 
268-3'/9. 
[1~] Clore, G.M,, Appalls0 E., Yamada, M,, Matsushima, K. and 
Gronenborn, A.M, (1989] J Biol. Chern, 264, 18907-18911. 
[IS} CIore, G,M.. Appalls, E., Yamada, M,. Matsushima, K and 
Gronenborn) A,M, (1990) Biochemistry 29, 1689-1696, 
[16] Dane, K., Andreasen, A,, Grondahl-Hansen, J,, Kristensen, 
P., Nielsen. L.S. and Skriver, L, 0985) Adv, Cancer Res. 44, 
139-266. 
414 
